NYSE:NBY
NovaBay Pharmaceuticals, Inc Stock News
$0.0949
+0.0049 (+5.44%)
At Close: May 03, 2024
Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests
06:20pm, Tuesday, 24'th Sep 2019
British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acte
NovaBay Pharmaceuticals Receives Approval for Distribution of Avenova in Australia
10:50am, Tuesday, 24'th Sep 2019
“We are pleased to receive approval to market Avenova in Australia and are planning to engage a distributor in the near term,” said Justin Hall, NovaBay president and CEO. “This marks another s
NovaBay Pharmaceuticals shares are trading lower. Not seeing any news to justify the price action.
12:00am, Friday, 20'th Sep 2019NovaBay Pharmaceuticals Receives Australian Therapeutic Goods Administration Approval For Avenov
12:00am, Wednesday, 18'th Sep 2019NovaBay Pharmaceuticals Names Finance Executive Jeff Zheng to its Board of Directors
10:50am, Monday, 16'th Sep 2019
Dr. Zheng will chair the nominating and corporate governance committee, and will serve on the audit and compensation committees. “Jeff brings us extensive corporate governance and financial experie
NovaBay Pharmaceuticals: Empery Asset Management Report 8.42% Passive Stake
12:00am, Thursday, 15'th Aug 2019
The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions. The preferred stock, the common stock con
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering
01:22pm, Friday, 09'th Aug 2019
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a secur
